NCT06215846View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

January 28, 2026

Conditions
Solid Tumor
Interventions
BIOLOGICAL

BioTTT001 injection

BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.

Trial Locations (1)

Unknown

The First Affiliated Hospital of China Medical Univeristy, Shenyang

All Listed Sponsors
lead

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

INDUSTRY